Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 303 participants.

Also called NCT06215586

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 303 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06215586
  • EudraCT 2023-508737-13
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Belgium, Bulgaria, Canada, Czechia, Germany, Hungary, Italy, Netherlands, New Zealand, Poland, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06215586. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-13 (actual); primary completion 2025-09-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
Acronym
Cycle-2-PEF
Condition
Heart Failure
Condition
Heart Failure Preserved Ejection Fraction
Condition
Cardiovascular Diseases
Condition
Heart Diseases
Intervention (Drug)
Tovinontrine (CRD-750)
Intervention (Drug)
Placebo
Lead sponsor
Cardurion Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06215586
Content hash
8a80fb213b2edad3aff9e62cd9e7c08fbc1796f43797a1afbab0b5e73865c490